Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCTURUS THERAPEUTICS HOLDINGS INC.

(ARCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Arcturus Therapeutics : to start clinical trial of COVID-19 vaccine in Vietnam

08/02/2021 | 10:30am EDT

Aug 2 (Reuters) - Arcturus Therapeutics Holdings Inc said on Monday its Vietnamese partner received regulatory approval to start a clinical trial of its COVID-19 vaccine candidate in the Southeast Asian country.

The partner Vinbiocare, a unit of Vietnam's biggest conglomerate Vingroup, has signed a deal for the domestic manufacturing rights to Arcturus' vaccines, including ARCT-154 that targets variants such as the fast-spreading Delta strain.

After successfully containing the virus for much of the pandemic, Vietnam has been battling a spike in COVID-19 infections caused by the Delta variant.

The country late last month extended movement restrictions in its business hub Ho Chi Minh City and another 18 cities and provinces throughout its south for another two weeks.

San Diego, California-based Arcturus said the study would test its mRNA-based candidate ARCT-154 in 21,000 adults in three phases and would be completely funded by Vinbiocare.

Pre-clinical data on the vaccine showed that it elicits neutralizing antibodies against COVID-19 variants, including the Delta strain.

Arcturus said ARCT-154 would be developed alongside its lead investigational COVID-19 vaccine, ARCT-021. (Reporting by Amruta Khandekar; Editing by Aditya Soni)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ARCTURUS THERAPEUTICS HOLDINGS INC. 2.41% 52.95 Delayed Quote.19.43%
VINGROUP JOINT STOCK COMPANY -1.27% 85600 End-of-day quote.-11.00%
All news about ARCTURUS THERAPEUTICS HOLDINGS INC.
09:14aHealth Care Stocks Edge Higher Premarket Wednesday
MT
08:05aARCTURUS THERAPEUTICS : Gets Vietnam's OK to Proceed With Phase 2, 3a Enrollment for Testi..
MT
07:03aARCTURUS THERAPEUTICS : Announces Approval from Vietnam Ministry of Health to Proceed into..
BU
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/08ARCTURUS THERAPEUTICS : to Participate in Citi's 16th Annual BioPharma Virtual Conference ..
BU
09/07ARCTURUS THERAPEUTICS : to Present at Upcoming Investor and Scientific Conferences
BU
08/26ARCTURUS THERAPEUTICS HOLDINGS INC. : Termination of a Material Definitive Agreement, Chan..
AQ
08/26Arcturus Therapeutics Holdings Inc. Announces the Resignation of Karah Parschauer from ..
CI
08/25ARCTURUS THERAPEUTICS : Citigroup Adjusts Price Target on Arcturus Therapeutics Holdings t..
MT
08/13NORTH AMERICAN MORNING BRIEFING : Blockbuster -3-
DJ
More news
Analyst Recommendations on ARCTURUS THERAPEUTICS HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 66,8 M - -
Net income 2021 -168 M - -
Net cash 2021 278 M - -
P/E ratio 2021 -8,45x
Yield 2021 -
Capitalization 1 364 M 1 364 M -
EV / Sales 2021 16,3x
EV / Sales 2022 2,64x
Nbr of Employees 118
Free-Float 85,1%
Chart ARCTURUS THERAPEUTICS HOLDINGS INC.
Duration : Period :
Arcturus Therapeutics Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCTURUS THERAPEUTICS HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 51,81 $
Average target price 78,46 $
Spread / Average Target 51,4%
EPS Revisions
Managers and Directors
Joseph E. Payne President, Chief Executive Officer & Director
Andrew H. Sassine Chief Financial Officer & Director
Peter C. Farrell Chairman
Padmanabh Chivukula Secretary, Chief Operating & Scientific Officer
Steven G. Hughes Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARCTURUS THERAPEUTICS HOLDINGS INC.19.43%1 364
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021